Friday, July 24, 2015
Albany Molecular Research (AMRI), a global contract research and manufacturing organization based in Albany, N.Y., has acquired all the outstanding shares of Gadea Pharmaceutical Group, a privately held company located in Valladolid, Spain, specializing in technically complex active pharmaceutical ingredients (APIs) and finished drug product. The purchase price was $174 million, including the issuance of 2.2 million shares of common stock to Gadea’s owners, valued at $43.8 million, with the balance paid in cash and through the assumption of existing debt.
Epic Sciences, a San Diego, Calif.-based developer of novel diagnostics to personalize and advance the treatment and management of cancer, has inked an agreement with Laboratory Corporation of America Holdings (LabCorp), a Burlington, N.C.-based healthcare diagnostics company, to provide circulating tumor cell (CTC) technology and support oncology clinical trials in Asia through Covance Drug Development.
Through a partnership with the Special Bacteriology Reference Laboratory at the Centers for Disease Control and Prevention (CDC), Thermo Fisher Scientific has developed an advanced software solution that enables global public health laboratories to directly access the CDC’s MicrobeNet online virtual reference lab database. Now, researchers can more quickly identify microbial pathogens potentially at the root of global outbreaks without needing to refer to multiple databases by instead utilizing one curated by subject matter experts in the field.
Charles River Laboratories International, a Wilmington, Mass.-based CRO, has entered into a definitive agreement to acquire Celsis International, a global provider of rapid bacterial detection systems for quality control testing in the biopharmaceutical and consumer products industries, for $212 million in cash. Celsis’s systems are principally used for product-release testing to help ensure the safe manufacture of drugs and consumer products.
Global CRO Parexel International has launched expanded services and capabilities in model-based drug development (MBDD) through its Quantitative Clinical Development (QCD) group. The Parexel QCD team also offers leadership in all strategic and quantitative aspects of clinical pharmacology for biopharmaceutical companies to help expedite drug development, minimize risk and support regulatory approval processes.